Login to Your Account



Analysts split on Xyrem patent settlement, but Jazz Pharmaceuticals shares bounce

By Marie Powers
News Editor

Thursday, April 6, 2017

Jazz Pharmaceuticals plc ended a nearly seven-year spat over Xyrem by granting Hikma Pharmaceuticals plc the right to sell an authorized generic version of the drug under its NDA in the U.S., beginning Jan. 1, 2023.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription